SCDM - Innovations/eSource Implementation Consortium
Task Force Check-in

Meeting called by: Mike Buckley
Type of meeting: Operations
Facilitator: Mike, Rakesh and Linda
Scribe: Mehdi Stambouli

Attendees:
1. Linda King
2. Rakesh Maniar
3. Kenneth Milstead
4. Shannon Labot
5. Denise Snyder
6. Meridith Zozus
7. Eugene Hayden
8. Monica Lawrence
9. Christopher Dunn
10. Mehdi Stambouli
11. Hugh Dai
12. Joe Dustin
13. Muzafar Mirza
14. Jason Colquitt
15. Shannon Roznoski

Anti-trust statement: ANTITRUST COMPLIANCE POLICY for complete policy see SCDM website under policies and procedures or Appendix 1 to these meeting minutes

The Society for Clinical Data Management (“SCDM”) has adopted a policy of strict compliance with applicable antitrust laws. Certain topics that may be considered anticompetitive are not proper subjects for discussion or consideration at any SCDM meeting of members, officers, trustees, committees or taskforces, whether formal or informal. While it is entirely appropriate to meet as an association to discuss common problems and areas of interest, an agreement taken to eliminate, restrict, or limit competition, such as price-fixing, boycotts, or allocation of markets, can be a per se violation of antitrust laws and lead to severe civil or criminal penalties.

Minutes

Discussion:

1. Discussed Breaking down into smaller groups to lead SCDM Projects discussed at Virtual F2F Summit.
   - TransCelerate FHIR Lab Project
   - Project Vulcan
   - Multi Trial Evaluations of HER-to-eCRF Technology

2. Recap of the 3 SCDM Projects.
   - TransCelerate FHIR Lab Project
     o Goal to direct from Site EHR to Sponsor system
   - Project Vulcan
3. Use case, all will be included in the January Connectathon
   - Pheno Packets
   - RWE/RWD
   - Schedule of activities

4. Onboarding Activities
   - Multi Trial Evaluations of HER-to-eCRF Technology
     - Looking for sponsors having trials coming up in the next year.
     - Looking for higher enrolling sites – at least 3 sites that will enroll at least 20 participants.
     - Run this in parallel with an existing protocol
     - CDER healthIT board meeting in January where this project will be discussed

3. Educational Opportunities
   - Use SCDM platforms for webinars/online courses to bring more engagement into the SCDM community.

Conclusions:

<table>
<thead>
<tr>
<th>Action items</th>
<th>Person responsible</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ Schedule meetings for participants interested in each project to meet to form teams, determine project meeting schedule, and picking Co-leads.</td>
<td>eSource Group</td>
<td>2/7/2021</td>
</tr>
<tr>
<td>✓ Volunteers to reach out to pick SCDM Project$_5$ that they can commit too.</td>
<td></td>
<td>2/7/2021</td>
</tr>
</tbody>
</table>

**Other Information**

Observers:
None.

Resources:

Special notes:
Appendix 1:

ANTITRUST COMPLIANCE POLICY

The Society for Clinical Data Management (“SCDM”) has adopted a policy of strict compliance with applicable antitrust laws. Certain topics that may be considered anticompetitive are not proper subjects for discussion or consideration at any SCDM meeting of members, officers, trustees, committees or taskforces, whether formal or informal. While it is entirely appropriate to meet as an association to discuss common problems and areas of interest, an agreement taken to eliminate, restrict, or limit competition, such as price-fixing, boycotts, or allocation of markets, can be a per se violation of antitrust laws and lead to severe civil or criminal penalties.

It is essential, therefore, that all necessary steps be taken by SCDM trustees, officers, staff and members (“Participants”) to prevent any SCDM meeting or activity from becoming a forum for the type of discussions which might lead to an understanding or agreement, expressed or implied, with respect to any essential element of competition. The following guidelines must be observed in connection with all SCDM meetings and activities:

1) Participants will adhere to competition rules, as applicable, prohibiting any discussion, understanding or agreement, however informal, or the exchange of information on:

   a) individual company prices, price changes, pricing strategies, terms of sales, price mark-ups, discounts, allowances, credit terms;
   b) costs of production or distribution, cost accounting formulae, methods of computing costs;
   c) individual company figures on or plans as to sources of supply, production, inventories, sales, marketing and promotion;
   d) any matters relating to individual suppliers or customers, including any attempted collective action that might have the effect of excluding suppliers or customers from the market;
   e) information as to future plans of individual companies concerning technology and investments;
f) Confidential research and development projects, budgets, spend, or priorities, including early stage
development targets, prioritization of targets or projects, R&D spend or forecasted spend on particular
development projects or targets, and plans for future R&D projects;
g) Avoiding or limiting research or development work or spend in certain areas or regarding certain
targets, or limiting work or spend on R&D generally;
h) A company’s business strategies for identifying potential R&D targets and evaluating continued
financial investment in the target throughout the R&D process;
i) Refusals to do business with particular investigators, suppliers, vendors, licensors, customers, or
competitors, or the suggestion that such a refusal or boycott might be appropriate or desirable;
j) The amount that a specific company pays for goods or services;
k) Future, current, or recent (i.e. within the last 90 days) prices, price changes, price quotations, pricing
policies or philosophies, price differentials, markups, discounts, allowances, including any significant
element of price, such as freight, credit, warranties, terms and conditions of sale;
l) Future, current, or recent (i.e. within the last 90 days) output, capacity, inventory levels or costs
(including production, down-time, inventory, distribution, or wage, salary or benefits cost);
m) The customers to whom a specific company does or does not sell, the territories in which a specific
company does or does not sell, or the product categories which a specific company does or does not
sell;
n) Plans concerning the future production, distribution, or marketing of particular products, or any other
statistics or data pertaining to a particular company’s business operations.

2) No member shall be compelled or coerced by SCDM or any other members into accepting or complying with any
industry standard, guideline, procedure, or recommendation developed by SCDM or any of its committees or
taskforces. No member is obligated to agree to accept or comply with any industry standard, guideline,
procedure, or recommendation developed by SCDM or any of its committees or taskforces.

3) Any standard, guideline, procedure, or recommendation developed by SCDM, its committees and taskforces
shall be solely and exclusively upon technical considerations and upon the merits of objective judgements and
thorough procedures and shall in no way be based upon any effort, intention, or purpose of any of its members
to reduce or eliminate competition in the sale, supply and finishing of products and services.

4) If information, materials, or reports of SCDM designed for the use of its members are significant to third parties
or any others in the industry, then such information, materials, or reports will be made available by SCDM to all
such persons, on such reasonable terms and conditions as it may prescribe, in order to carry out its purposes.

5) To the extent that the purpose of any SCDM committee or taskforce requires collaboration by two or more
members or representatives of members in furthering those purposes, the members or representatives of
members shall undertake such collaboration only to the extent necessary to achieve such purposes, and shall
report the results of any such collaboration to the committee or taskforce chairs. Any such collaboration shall
exclude:
   a) The exchange of information between or among members relating to any aspect of competition among
      the members, except to the extent that the exchange is reasonably required to accomplish the purposes
      of the committee or taskforce and is unlikely to have any impact on competition between or among
      members. In case of doubt, the collaborating members should consult legal counsel with regard to the
      proposed exchange or the format in which the exchange should take place.
   b) Any agreement or conduct restricting efforts to discover, develop, or produce any product by any
      member, limiting the manner in which any member markets or promotes any product, requiring the
      purchase or sale of any product by any member, limiting or discouraging members from engaging in
      any specific research and development project or reducing R&D generally; or limiting the sharing of
      intellectual property by, between, or among members. The collaborating members should consult
      legal counsel with respect to any limitation SCDM may desire to lawfully impose with respect to the
      result of the collaboration.

6) For all committee and taskforce meetings organized and attended there must be
   a) a written agenda circulated in advance of the meeting;
   b) written minutes, submitted for approval to chairs and posted for participants;

7) Working groups and participation criteria for meetings must be transparent and non-discriminatory.
Committees and taskforces of SCDM may adopt additional guidelines or other policies as a means of mitigating any risk that could result from any meeting or activity of a committee or taskforce or be perceived as resulting in any reduction in competition between any members, whether intentionally or otherwise.

All SCDM meetings must be conducted in accordance with this Policy. Any questions should be addressed to legal counsel.

Adopted August 2018